Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | DKY709 |
Trade Name | |
Synonyms | DKY 709|DKY-709 |
Drug Descriptions |
DKY709 modulates the activity of E3 ubiquitin ligase resulting in proteosomal degradation of IKZF2, which potentially leads to activation of T-cell mediated antitumor immune response (NCI Thesaurus). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C180613 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
DKY709 | DKY709 | 0 | 1 |
DKY709 + Spartalizumab | DKY709 Spartalizumab | 0 | 1 |